Formulary Watch |

The FDA is considering a monthly IV maintenance dose of Leqembi to treat people with Alzheimer’s disease. The action date is set for Jan. 25, 2025.

Included in this review will be 11 drugs that ICER assessed for cost-effectiveness in 2022. New this year is an assessment for consumer accessibility of drugs, including the burdens of prior authorization and patient cost-sharing measures.

Vanity Fair shines a light on how fake Ozempic and other semaglutide products have found their way into the U.S. supply chain.

Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.

LucyRx will begin providing pharmacy benefit services to self-insured employers, covering about half a million lives, beginning in January 2025.

Onyda XR is a liquid form of clonidine that can be used as monotherapy or as adjunctive therapy for patients 6 years of age and older with ADHD.

In the United States, spending on oncology therapies rose to $99 billion in 2023, and is expected to grow to nearly $180 billion in 2028, finds a recent report by IQVIA Institute for Human Data Science.

Yesafili and Opuviz are approved to treat patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

The new program will launch in January 2025 and provide plan sponsors greater predictability of pharmacy spend.

Upstaza is a one-time gene therapy to treat patients 18 months and older with AADC deficiency. It has a review date of Nov. 13, 2024.

New KFF poll finds most of the adults who have taken GLP-1 therapies have diabetes or heart disease. But 38% said they have used for these drugs solely to lose weight.

An analysis of claims data shown Orladeyo can reduce hospitals and emergency room visit of patients with the rare genetic condition hereditary angioedema.

If approved, abelacimab could yield cost savings in preventing stroke in patients with atrial fibrillation due to its ability to prevent bleeding.